SCHEMBL2911571

SCHEMBL2911571

CCNC(=O)Nc1ccc(C)c(-c2ccc(C(=O)O)cc2)c1

nearest known ligand 0.51

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 14/20 0.51
RXRA P19793 1/20 0.46
ABL1 P00519 1/20 0.45
HSPB1 P04792 1/20 0.44
RARB P10826 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2912882 0.82 MAPK14 (0.62) MAPK14ABL1
SCHEMBL2914161 0.82 MAPK14 (0.67) MAPK14RXRA
SCHEMBL13614142 0.81 NAMPT (0.58)
SCHEMBL2913317 0.81 MEN1 (0.59) MAPK14
SCHEMBL2912590 0.80 MAPK14 (0.50) MAPK14RXRAHSPB1
SCHEMBL2912653 0.78 IP6K1 (0.49) MAPK14RXRA
SCHEMBL2348556 0.78 MAPK14 (0.67) MAPK14HSPB1RARB
SCHEMBL2913670 0.78 MEN1 (0.53) MAPK14
SCHEMBL2910143 0.77 NPC1 (0.65) MAPK14
SCHEMBL26463986 0.77 ALDH1A1 (0.62)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1940786-B1 BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C ARROW THERAPEUTICS LTD (GB) 2010-08-18 EP disclosed
US-20080255105-A1 Biphenyl Derivatives and Their Use in Treating Hepatitis C ARROW THERAPEUTICS LIMITED (GB) 2008-10-16 US disclosed
EP-1940786-A1 BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C Arrow Therapeutics Limited (GB) 2008-07-09 EP disclosed
WO-2007031791-A1 BIPHENYL DERIVATIVES AND THEIR USE IN TREATING HEPATITIS C ARROW THERAPEUTICS LIMITED (GB) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080255105-A1 Biphenyl Derivatives and Their Use in Treating Hepatitis C NR4A1, NR0B1, NR1H4 MAPK14 4315/4885RXRA 25/4885ABL1 849/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.